Sports Betting Addiction Lawsuit Sports betting addiction lawsuits are being investigated for college students and young adults who developed gambling problems after using apps like FanDuel and DraftKings, alleging that the platforms failed to warn about the addictive nature of their features and marketing practices.
Nitrous Oxide Lawsuit Individuals who suffered harm, or families who lost a loved one after using nitrous oxide products may be eligible for financial compensation through a nitrous oxide lawsuit.
Hair Relaxer Lawsuit Regular exposure to chemicals in hair relaxer may cause uterine cancer, ovarian cancer and other injuries. Women diagnosed with cancer may be eligible for settlement benefits.
Depo-Provera Lawsuit Depo-Provera lawsuits are being investigated for women who developed meningioma brain tumors after receiving Depo-Provera birth control shots, claiming that Pfizer failed to adequately disclose side effects.
Ozempic Lawsuit Lawyers are pursuing Ozempic lawsuits, Wegovy lawsuits and Mounjaro lawsuits over gastroparesis or stomach paralysis, which can leave users with long-term gastrointestinal side effects
Suboxone Tooth Decay Lawsuit Lawsuits are being pursued by users of Suboxone who experienced tooth loss, broken teeth or required dental extractions. Settlement benefits may be available.
Change Healthcare Lawsuit Lawyers are reviewing Change Healthcare class action lawsuits for individuals who had their personal information stolen due to the data breach.
Bard PowerPort Lawsuit Serious and life-threatening injuries have been linked to problems with Bard PowerPort. Lawsuits are now being pursued by individuals who suffered injuries from the implantable port catheter fracturing or migrating.
AngioDynamics Port Catheter Lawsuit Serious and life-threatening injuries have been linked to problems with Bard PowerPort. Lawsuits are now being pursued by individuals who suffered injuries from the implantable port catheter fracturing or migrating.
Processed Food Lawsuit Lawsuits are being pursued against the food industry over their manufacturing and advertising of ultra-processed foods, which have caused a generation of children to face an increased risk of developing childhood diabetes and other chronic illnesses.
Gilenya Side Effects Evaluated in ISMP Report October 3, 2014 Irvin Jackson Add Your Comments An analysis of adverse event reports submitted to the FDA suggests that side effects of Gilenya, a multiple sclerosis drug, may be linked to a risk of heart rhythm problems, as well as infections. In the latest Quarterwatch report (PDF) by the Institute For Safe Medication Practices (ISMP), at least 2,716 reports involving problems with Gilenya were identified over a one-year period. The report seems to back up Gilenya heart warnings added in 2012, and raise further questions about how fast the FDA allowed the drug to enter the market. Do You Know about… SPORTS BETTING ADDICTION LAWSUITS FOR YOUNG ADULTS Gambling addiction and severe financial losses have been linked to popular sports betting platforms like DraftKings, FanDuel, and Caesars. Lawsuits are being filed by young adults and students who were targeted by deceptive promotions, addictive app features, and aggressive marketing tactics. See if you qualify for a sports betting addiction lawsuit. Learn More SEE IF YOU QUALIFY FOR COMPENSATION Do You Know About… SPORTS BETTING ADDICTION LAWSUITS FOR YOUNG ADULTS Gambling addiction and severe financial losses have been linked to popular sports betting platforms like DraftKings, FanDuel, and Caesars. Lawsuits are being filed by young adults and students who were targeted by deceptive promotions, addictive app features, and aggressive marketing tactics. See if you qualify for a sports betting addiction lawsuit. Learn More SEE IF YOU QUALIFY FOR COMPENSATION Gilenya Concerns Gilenya (fingolimod) was introduced by Novartis for treatment of multiple sclerosis in 2010, through a controversial fast-track FDA approval program, which is designed to allow promising medications onto the market faster, with limited testing. The medication is now used by about 70,000 people throughout the world to reduce flare-ups and delay the onset of physical disability caused by MS. However, serious questions have been raised about whether Gilenya and other medications approved through the expedited process were properly vetted. “Adverse event reports for the most recent 12 months showed the cardiac risks were neither rare nor hypothetical,” according to the ISMP report. “We identified 473 cases of heart rhythm disturbance, primarily bradycardia and heart block. They include 13 patient deaths, 11 cases classified as life-threatening and 141 resulting in hospitalization.” The ISMP report also found 348 cases of macular degeneration or other side effects affecting the eyes, and 172 reports of viral infections. The ISMP report concluded that reports of serious injury was linked to 17% per patient-year of exposure. Fast-Track Approval Garnered Criticism According to an editorial published in the Journal of the American Medical Association (JAMA) in 2012, Gilenya was cited as an example of a medication that may have been approved too fast. Critics highlighted concerns with the program, indicating that at least seven major safety issues were identified during Gilenya clinical trials, including heart problems, liver toxicity, increased risk of infection, reduced pulmonary function, teratogenicity, macular edema and a potentially risk of cancer. Clinical trials involving doses of 5mg and 2.5mg were halted due to safety reasons, leading the FDA to approve Gilenya at the lowest dose possible of 0.5mg. Despite concerns over the safety of Gilenya when it was reviewed, the FDA agreed to fast-track the drug’s approval with only minimal testing because the drug was identified as a crucial medication that addressed needs that were not met by other treatments. “Prior to approval, the FDA advisory committee reviewing fingolimod voted unanimously that the drug should be studied at a lower dose to see if safety could be improved without loss of efficacy,” the ISMP points out in this latest evaluation of Gilenya side effects. “The logic was compelling because clinical trials at three doses higher than the approved 0.5 mg daily had to be halted for safety, and the drug had never been studied at dose below 0.5 mg. Despite not knowing the optimum dose, the FDA approved fingolimod on the condition that a lower dose be studied. The Phase IV study of a lower dose is now under way and scheduled for completion in 2016, one year after the date specified at the time of approval.” In May 2012, the FDA added new warnings about the risk of Gilenya heart side effects after a patient died within 24 hours after taking the drug. Doctors were advised not to prescribe Gilenya to patients who have a history of heart problems or who take drugs that lower their heart rates. When the drug is given to patients with heart problems, health regulators indicated that they should be monitored by ECG before the first dose and continuously for six hours afterwards. Tags: Drug Side Effects, Gilenya, Heart Rhythm, Infection, Multiple Sclerosis More Lawsuit Stories Court Outlines Requirements for Depo-Provera Lawsuit Proof of Use, Type of Meningioma Tumor May 15, 2025 Ninja Foodi Recall Lawsuit Alleges Pressure Cooker Explosion Risks Were Known by SharkNinja May 15, 2025 Georgia Lawmakers Agree To Shield Bayer From Roundup Cancer Lawsuits May 15, 2025 1 Comments Cynthia February 27, 2015 I’ve been on Gilenya since the sping of 2010. I didnt have any symptoms at first, but over the last two years, I’ve been on the decline. Twice I went to the doctor’s office about chest pains, and one visit to the E.R. My blood pressure has been up EVERY VISIT, as well as my cholesterol. I was put on prescriptions for both. Chest pain still continued, as well as, dizzness and lightheadedness. I decided to stop taking Gilenya the end of January 2015, but symptoms continues. Will see new Neurologist soon. Share Your CommentsFirst Name*Last NameEmail* Shared Comments*This field is hidden when viewing the formI authorize the above comments be posted on this page Yes No Post Comment I authorize the above comments be posted on this page Weekly Digest Opt-In Yes, send me a weekly email with the latest lawsuits, recalls and warnings. Want your comments reviewed by a lawyer?To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.Contact Phone #Alt Phone #Private CommentsNOTE: Providing information for review by an attorney does not form an attorney-client relationship.CAPTCHAGA SourceGA CampaignGA MediumGA ContentGA TermEmailThis field is for validation purposes and should be left unchanged. Δ MORE TOP STORIES Court Outlines Requirements for Depo-Provera Lawsuit Proof of Use, Type of Meningioma Tumor (Posted: today) As new Depo-Provera lawsuits continue to be filed, the judge presiding over the litigation has established key criteria for establishing proof of Depo-Provera use and medical documentation confirming a meningioma diagnosis. MORE ABOUT: DEPO-PROVERA LAWSUITDepo Shot Lawsuit Filed Over Serious Brain Tumor Injuries (05/07/2025)Lawsuit Alleges Depo-Provera Migraines, Headaches Led to Meningioma Brain Tumor Diagnosis (05/01/2025)Depo-Provera Hearing Loss Lawsuit Filed Over Brain Tumor Side Effects (04/22/2025) BioZorb Implant Lawsuit Alleges Tissue Marker Caused Swelling, Fluid Buildup and Chronic Pain (Posted: yesterday) A Massachusetts woman’s injuries from a failed tissue marker that was recently recalled led to the need for physical therapy, according to a BioZorb implant lawsuit. MORE ABOUT: BIOZORB LAWSUITFour Women File BioZorb Lawsuit Over Breast Tissue Marker Failures and Injuries (05/05/2025)Lawsuit Claims BioZorb Marker Caused Chronic Pain, Multiple Surgeries After Lumpectomy (04/14/2025)Four BioZorb Breast Tissue Marker Lawsuits Selected for Bellwether Trials (04/02/2025) Lawyers Selected 32 Hair Relaxer Lawsuits for Bellwether Discovery in MDL (Posted: 2 days ago) Hair relaxer lawsuit plaintiffs and defendants have selected 32 claims to be prepared for early test trials, focusing on ovarian, uterine and endometrial cancer injuries. MORE ABOUT: HAIR RELAXER LAWSUITFormaldehyde Found in Range of Personal Care Products Used Primarily by Black and Latina Women (05/14/2025)Hair Relaxer Settlement Master Appointed To Oversee Negotiations To Resolve Cancer Lawsuits (04/29/2025)Hair Relaxer Lawyers To Meet With MDL Judge Amid “Contentious” Disputes Over Bellwether Discovery Plans (04/23/2025)
Court Outlines Requirements for Depo-Provera Lawsuit Proof of Use, Type of Meningioma Tumor May 15, 2025
Ninja Foodi Recall Lawsuit Alleges Pressure Cooker Explosion Risks Were Known by SharkNinja May 15, 2025
Court Outlines Requirements for Depo-Provera Lawsuit Proof of Use, Type of Meningioma Tumor (Posted: today) As new Depo-Provera lawsuits continue to be filed, the judge presiding over the litigation has established key criteria for establishing proof of Depo-Provera use and medical documentation confirming a meningioma diagnosis. MORE ABOUT: DEPO-PROVERA LAWSUITDepo Shot Lawsuit Filed Over Serious Brain Tumor Injuries (05/07/2025)Lawsuit Alleges Depo-Provera Migraines, Headaches Led to Meningioma Brain Tumor Diagnosis (05/01/2025)Depo-Provera Hearing Loss Lawsuit Filed Over Brain Tumor Side Effects (04/22/2025)
BioZorb Implant Lawsuit Alleges Tissue Marker Caused Swelling, Fluid Buildup and Chronic Pain (Posted: yesterday) A Massachusetts woman’s injuries from a failed tissue marker that was recently recalled led to the need for physical therapy, according to a BioZorb implant lawsuit. MORE ABOUT: BIOZORB LAWSUITFour Women File BioZorb Lawsuit Over Breast Tissue Marker Failures and Injuries (05/05/2025)Lawsuit Claims BioZorb Marker Caused Chronic Pain, Multiple Surgeries After Lumpectomy (04/14/2025)Four BioZorb Breast Tissue Marker Lawsuits Selected for Bellwether Trials (04/02/2025)
Lawyers Selected 32 Hair Relaxer Lawsuits for Bellwether Discovery in MDL (Posted: 2 days ago) Hair relaxer lawsuit plaintiffs and defendants have selected 32 claims to be prepared for early test trials, focusing on ovarian, uterine and endometrial cancer injuries. MORE ABOUT: HAIR RELAXER LAWSUITFormaldehyde Found in Range of Personal Care Products Used Primarily by Black and Latina Women (05/14/2025)Hair Relaxer Settlement Master Appointed To Oversee Negotiations To Resolve Cancer Lawsuits (04/29/2025)Hair Relaxer Lawyers To Meet With MDL Judge Amid “Contentious” Disputes Over Bellwether Discovery Plans (04/23/2025)